Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Stock analysts at StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Get Free Report) in a report released on Saturday. The firm set a “sell” rating on the stock. A ...

It’s woolly hat weather in Oxford and though the porter in the lodge at New College is friendly, it’s a relief to see Professor Masud Husain quickly appear to take me to a warm room for our interview.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Free Report) has received a consensus rating of “Hold” from the five brokerages that are currently covering the stock, Ratings reports. Four equities ...

Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $1.52 Per Share Related to ...

During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.